RenovoRx, Inc. RNXT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-28.17
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.1M | -$11.2M | $796,000 | -$11.0M | $5.4M |
| 2024 | $43,000 | -$8.8M | $43,000 | -$9.1M | $4.5M |
| 2023 | — | -$10.2M | — | — | $3.0M |
| 2022 | — | -$9.9M | — | — | $6.2M |
| 2021 | — | -$6.3M | — | — | $15.3M |
| 2020 | — | -$3.8M | — | — | -$14.7M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -28.17 (distress)
- Working capital / assets 0.733
- Retained earnings / assets -7.583
- EBIT / assets -1.545
- Equity / liabilities 2.028
Source: SEC EDGAR filings · CIK 0001574094 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.